Predicting response to therapy in chronic hepatitis C: An approach combining interleukin-28B gene polymorphisms and clinical data
✍ Scribed by José M Ladero; Elena García Martin; Cristina Fernández; Miguel Carballo; María J Devesa; Carmen Martínez; Avelina Suárez; Manuel Díaz-Rubio; José A Agúndez
- Book ID
- 108954235
- Publisher
- John Wiley and Sons
- Year
- 2012
- Tongue
- English
- Weight
- 156 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0815-9319
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Up to 30% of liver transplants will develop graft cirrhosis within 5 years after liver transplantation (LT) due to recurrent HCV-infection forwarding accelerated graft damage. Genetic variants of cytokines involved in the immune response may contribute to the degree of graft inflammation, fibrosis p
Genetic variation near the IL28B gene and substitution of amino acid (aa) 70 and 91 in the core region of hepatitis C virus (HCV) genotype 1b can predict the response to pegylated interferon (PEG-IFN)/ribavirin combination therapy, but its impact on triple therapy of telaprevir/PEG-IFN/ribavirin is
## Abstract Hepatitis C virus (HCV) genotype 1a is rare in Japanese patients and the clinical characteristics of this genotype remain unclear. The interferon (IFN) sensitivity‐determining region (ISDR) and single‐nucleotide polymorphisms (SNPs) of interleukin‐28B (IL28B) among patients with HCV gen